

Research Article

Melatonin Attenuates ox-LDL-Induced Endothelial Dysfunction by Reducing ER Stress and Inhibiting JNK/Mff Signaling

Peng Li ^{1,2}, Changlian Xie,³ Jiankai Zhong,⁴ Zhongzhou Guo,⁵ Kai Guo ⁶,
and Qiuyun Tu ¹

¹Department of Gerontology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China

²Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China

³Intensive Care Unit, The Traditional Chinese Medicine Hospital, Zhongshan, Guangdong Province 528400, China

⁴Department of Cardiology, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong Province 528308, China

⁵Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province 510515, China

⁶Cardiovascular Medicine Department, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong Province 510317, China

Correspondence should be addressed to Peng Li; lipeng_sysu@126.com, Kai Guo; guokai154556@i.smu.edu.cn, and Qiuyun Tu; 1147129858@qq.com

Received 5 January 2021; Revised 4 February 2021; Accepted 11 February 2021; Published 4 March 2021

Academic Editor: Yun-dai Chen

Copyright © 2021 Peng Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Endothelial dysfunction, which is characterized by damage to the endoplasmic reticulum (ER) and mitochondria, is involved in a variety of cardiovascular disorders. Here, we explored whether mitochondrial damage and ER stress are associated with endothelial dysfunction. We also examined whether and how melatonin protects against oxidized low-density lipoprotein- (ox-LDL-) induced damage in endothelial cells. We found that CHOP, GRP78, and PERK expressions, which are indicative of ER stress, increased significantly in response to ox-LDL treatment. ox-LDL also induced mitochondrial dysfunction as evidenced by decreased mitochondrial membrane potential, increased mitochondrial ROS levels, and downregulation of mitochondrial protective factors. In addition, ox-LDL inhibited antioxidative processes, as evidenced by decreased antioxidative enzyme activity and reduced Nrf2/HO-1 expression. Melatonin clearly reduced ER stress and promoted mitochondrial function and antioxidative processes in the presence of ox-LDL. Molecular investigation revealed that ox-LDL activated the JNK/Mff signaling pathway, and melatonin blocked this effect. These results demonstrate that ox-LDL induces ER stress and mitochondrial dysfunction and activates the JNK/Mff signaling pathway, thereby contributing to endothelial dysfunction. Moreover, melatonin inhibited JNK/Mff signaling and sustained ER homeostasis and mitochondrial function, thereby protecting endothelial cells against ox-LDL-induced damage.

1. Introduction

Endothelial dysfunction is associated with a variety of cardiovascular disorders such as ischemic heart disease, myocardial infarction, postinfarction heart remodeling, diabetic cardiomyopathy, and hypertension [1–3]. The cardioprotective effects of several clinical drugs, including statins, aspirin,

and clopidogrel, are reportedly associated with endothelial protection [4, 5]. In addition, many risk factors, such as oxidized low-density lipoprotein (ox-LDL), blood flow shear force, inflammation cytokines, oxidative stress, and septic shock, contribute to endothelial dysfunction. Among these risk factors, endothelial cells are particularly vulnerable to ox-LDL-induced stress through unknown mechanisms

[6–8]. Increases in ox-LDL result in decreased proliferative ability, impaired migratory response, increased apoptotic index, and reduced regenerative capability in endothelial cells [9–11]. Although many studies have examined the relationship between ox-LDL and pathological alterations in endothelial cells *in vivo* and *in vitro*, the key molecular mechanisms underlying ox-LDL-associated endothelial dysfunction have not been fully explained, and few effective therapeutic drugs are available for patients with endothelial dysfunction.

Endoplasmic reticulum (ER) stress is an adaptive response that regulates protein synthesis and folding within cells [6]. Moderate activation of ER stress is associated with timely removal of damaged or unfolded proteins, thereby contributing to protein quality control [12]. Interestingly, excessive induction of ER stress contributes to abnormal degradation of damaged proteins and activation of caspase-dependent cell apoptosis [13]. ER-related cell apoptosis is characterized by increased levels of CHOP and caspase-12 [14, 15]. In addition, previous studies have reported a close relationship between endothelial dysfunction and ER stress [16]. Excessive ER stress promotes calcium overload, leading to spasms in endothelial cells [17]. Migratory response and angiogenesis might also be affected by ER stress because of its connections to synthesis and secretion of proteins like vascular endothelial growth factor (VEGF), which is necessary for angiogenesis [18, 19]. In addition to the ER, the mitochondria are also responsible for energy supply and redox balance within endothelial cells [20, 21]. Impaired mitochondrial function resulting from mitochondrial fragmentation and decreased mitochondrial autophagy can act as an upstream regulator of endothelial dysfunction [22, 23]. Many physiological processes, such as endothelial cell movement, growth, proliferation, and regeneration, are highly dependent on mitochondrial function [24–26]. Mitochondrial damage reduces the available ATP in endothelial cells and therefore contributes to endothelial dysfunction. Recent studies report that mitochondrial damage is regulated by the JNK/Mff signaling pathway in the context of cardiac ischemia-reperfusion injury [27–29]. However, this mechanism has not been verified in ox-LDL-treated endothelial cells.

Melatonin is a classical cardioprotective drug with multiple effects on endothelial function. Melatonin treatment attenuates microvascular damage during ischemia-reperfusion injury [30, 31]. Melatonin also attenuates endothelial dysfunction in diabetic cardiomyopathy [32]. Furthermore, melatonin inhibits oxidative stress, calcium overload, and inflammation response in endothelial cells under different disease models [33, 34]. In the present study, we examined whether ox-LDL-induced endothelial dysfunction is associated with ER stress and JNK/Mff signaling pathway activation. We also conducted experiments to understand whether melatonin improves endothelial function by altering ER stress and the JNK/Mff signaling pathway.

2. Materials and Methods

2.1. Cell Line Culture. Human umbilical vein endothelial cells (HUVECs) were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were cultured

in RPMI 1640 (HyClone, Logan, UT, USA) containing 10% FBS (Gibco, Rockville, MD, USA) and maintained in a 37°C, 5% CO₂ incubator [35]. HUVECs were incubated with oxidized low-density lipoprotein (ox-LDL) at a concentration of 50 µg/mL according to a recent report [36]. To observe the protective effects of melatonin on ox-LDL-treated HUVECs, melatonin was added to the culture medium at a concentration of 5 µM based on a previous study [37].

2.2. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium Bromide (MTT) Assay. HUVECs were plated on 96-well plates. After 24 h, 48 h, and 72 h of proliferation, 10 µL MTT (Beyotime, Shanghai, China) was added to each well for 4 h. The cells were then treated with 100 µL dimethyl sulfoxide (DMSO; Sigma) for 2 h. Finally, the optical density (OD) value at 490 nm was measured using a spectrophotometer [38].

2.3. CCK-8 Assay. HUVECs were seeded onto 96-well plates and then incubated for 24, 48, 72, or 96 h. The CCK-8 reagent was then added to each well and then incubated for 4 h. The absorbance value of each well was measured at 490 nm [39].

2.4. Enzyme-Linked Immunosorbent Assay (ELISA). HUVECs at a density of 1×10^5 cells/well were cultured in 96-well plates at 37°C with 5% CO₂ for 24 hours. Cell culture supernatant was then collected, and GSH, GPX, and SOD levels were quantified using the corresponding ELISA kits purchased from R&D (San Diego, CA, USA) [40]. OD values at 450 nm absorbance were measured using an ELX808 Absorbance Reader (BioTek, London, UK) [41].

2.5. Mitochondrial Membrane Potential (MMP) Assessment. MMP was assessed using the JC-1 mitochondrial membrane potential assay kit (C2006, Beyotime, Shanghai, China) as described in a previous study [42]. HUVECs were collected after treatment with melatonin in the presence of ox-LDL. The cells were then incubated with 5 µM JC-1 staining kit reagent at 37°C for 30 minutes in the dark [43]. Finally, cells were analyzed using the Guava easyCyte Benchtop Flow Cytometer (BR168323; Luminex, Austin, TX, USA) with Kaluza C Analysis Software (version 2.1, Beckman Coulter, Indianapolis, IN, USA) [44].

2.6. Western Blot. Protein expression levels were determined via western blot as previously described [45]. After cell collection, protein lysis and extraction were performed using RIPA lysis buffer (R0278, Sigma-Aldrich, USA), and the concentration of extracted protein was measured using the Bicinchoninic acid (BCA) protein assay kit (AR0146, Boster Bio, Pleasanton, CA, USA) [46]. Then, 20 µg protein lysates samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; P0012AC, Beyotime, China) and transferred onto polyvinylidene fluoride (PVDF) membranes (FFP36, Beyotime, China), which were blocked with fat-free milk (5%) for 2 hours and incubated with primary antibodies at 4°C overnight; β -actin was used as internal control [47, 48]. The membranes were then incubated in secondary horseradish peroxidase- (HRP-) conjugated antibodies at room temperature for 1 hour and washed three times using tris-buffered




FIGURE 1: Melatonin attenuates ox-LDL-induced endothelial dysfunction. (a) HUVECs were treated with melatonin in the presence of ox-LDL. Cell viability was measured via MTT assay. (b) CCK-8 was used to measure the proliferative capacity of HUVECs after ox-LDL treatment. (c) A transwell assay was used to evaluate cell migratory response. (d) ELISA was used to analyze caspase-3 activity. [#] $p < 0.05$ vs. the control group, ^{*} $p < 0.05$ vs. the ox-LDL group.

saline Tween (TBST, T196393, Aladdin, China). Protein bands were visualized using the enhanced chemiluminescence (ECL) kit (P0018FS, Beyotime, China). Gray band density values were analyzed in the iBright CL1500 Imaging System (A44240, Thermo Fisher Scientific, USA) and calculated using ImageJ (version 5.0, Bio-Rad, Hercules, CA, USA) [49].

2.7. Detection of Caspase-3 Activity. Caspase-3 activity was evaluated using the caspase-3 activity assay kit (Beyotime) as previously described [50]. Briefly, HUVECs were seeded on 24-well plates and incubated with melatonin in the presence of ox-LDL for 48 h. The cells were then collected, and caspase-3 activity assay kit was measured [51].

2.8. Transwell Assay. For the migration assay, HUVECs were placed in the upper chamber of transwells [52]. For the invasion assay, the upper chamber was treated with Matrigel before cells were added. After incubation for 48 h,

cells that had migrated to or invaded the lower chamber were stained with 0.1% crystal violet and quantified using a microscope [53].

2.9. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). Samples were incubated with TRIzol reagent (Invitrogen) to extract total RNA [54]. CRNDE, miR-4262, and ZEB1 cDNA were synthesized using the All-in-One™ cDNA Synthesis Kit (FulGen, Guangzhou, China) [55]. Subsequently, qRT-PCR was performed using SYBR green (Applied Biosystems, Foster City, CA, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal reference (56).

2.10. Statistical Analysis. All experiments were repeated three times. Data are presented as means \pm standard deviation (SD). SPSS 17.0 software was used for statistical analyses. Student's *t*-tests and one-way analyses of variance (ANOVA) were used to identify differences between groups. $p < 0.05$ was considered statistically significant.

3. Results

3.1. Melatonin Attenuates ox-LDL-Induced Endothelial Dysfunction. After ox-LDL was administered to induce endothelial dysfunction, melatonin was added to the growth medium to evaluate any protective actions. First, cell viability was measured using an MTT assay. As shown in Figure 1(a), compared to the control group, endothelial cell viability was significantly reduced by exposure to ox-LDL. Interestingly, melatonin reversed this ox-LDL-induced cell damage. Endothelial cell proliferation capacity was also measured in a CCK-8 assay. As shown in Figure 1(b), compared to the control group, ox-LDL exposure progressively reduced endothelial cell proliferation. Again, melatonin reversed this ox-LDL-induced effect by increasing endothelial cell proliferative capacity. Migratory response in endothelial cells is also important for angiogenesis. A transwell assay was therefore used to analyze alterations in endothelial cell migratory response. As shown in Figure 1(c), compared to the control group, ox-LDL significantly reduced the number of endothelial cells that migrated, and melatonin reversed this effect. Finally, cell apoptosis was monitored using a caspase-3 activity assay. As shown in Figure 1(d), compared to the control group, caspase-3 activity in endothelial cells was significantly reduced in the ox-LDL group, suggesting that ox-LDL treatment induced cell apoptosis. Finally, melatonin treatment prevented ox-LDL-induced upregulation of caspase-3 activity, suggesting that melatonin has antiapoptotic effects in the presence of ox-LDL.

3.2. Melatonin Alleviates ox-LDL-Induced ER Stress. Changes in ER stress were evaluated to identify the molecular mechanism underlying ox-LDL-mediated endothelial dysfunction. First, ER stress biomarkers were analyzed by qPCR. As shown in Figures 2(a)–2(d), compared to the control group, transcription of CHOP, GRP78, and PERK was significantly elevated after ox-LDL treatment. However, melatonin inhibited this upregulation. To confirm that transcriptional activation of ER stress biomarkers is also associated with




FIGURE 2: Melatonin alleviates ER stress during ox-LDL treatment. (a–c) HUVECs were treated with melatonin in the presence of ox-LDL. qPCR was then used to measure CHOP, GRP78, and PERK transcription. (d–g) Proteins were isolated from treated HUVECs, and expression of CHOP, GRP78, and PERK proteins was evaluated using western blots. # $p < 0.05$ vs. the control group, * $p < 0.05$ vs. the ox-LDL group.

upregulation of ER stress-related proteins, western blots were used to quantify expression of proteins involved in ER stress initiation, augmentation, and execution. As shown in Figures 2(e)–2(g), compared to the control group, CHOP, GRP78, and PERK protein expressions rapidly increased as a result of ox-LDL treatment. Furthermore, melatonin treatment inhibited upregulation of ER stress-related proteins, suggesting that melatonin can inhibit ER stress in ox-LDL-treated endothelial cells.

3.3. Melatonin Sustains Mitochondrial Function in ox-LDL-Treated Endothelial Cells. In addition to ER stress, we also examined the effects of ox-LDL on mitochondrial dysfunction. ox-LDL significantly increased mitochondrial oxidative stress as indicated by a mitochondrial ROS probe assay

(Figures 3(a) and 3(b)). Interestingly, melatonin treatment strongly inhibited mitochondrial ROS production in endothelial cells. Next, we examined the regulatory effects of melatonin on mitochondrial membrane potential. As shown in Figures 3(c) and 3(d), compared to the control group, ox-LDL treatment disrupted mitochondrial membrane potential, as indicated by decreased red JC-1 probe fluorescence. Interestingly, melatonin treatment significantly reversed this disruption of mitochondrial membrane potential. ox-LDL treatment also significantly decreased the expression of mitochondrial protective factors Bcl-2 and c-IAP1 (Figures 3(e) and 3(f)), and melatonin treatment again reversed this decrease. Taken together, these results indicate that melatonin protected mitochondrial function in endothelial cells.




FIGURE 3: Melatonin sustains mitochondrial function in ox-LDL-treated endothelial cells. (a, b) Mitochondrial ROS production was examined using a mitochondrial ROS probe. HUVECs were treated with melatonin in the presence of ox-LDL. (c, d) Mitochondrial membrane potential was determined using the JC-1 probe. (e, f) qPCR was used to measure cIAP1 and Bcl-2 transcription in response to ox-LDL treatment with or without melatonin. [#]*p* < 0.05 vs. the control group, ^{*}*p* < 0.05 vs. the ox-LDL group.

3.4. Melatonin Inhibits Oxidative Stress in ox-LDL-Treated Endothelial Cells. In addition to ER stress and mitochondrial dysfunction, we also explored whether ox-LDL induces oxidative stress that contributes to endothelial dysfunction. As shown in Figures 4(a)–4(c), compared to the control group, ox-LDL significantly inhibited the activity of antioxidative enzymes. Interestingly, melatonin treatment reversed this

inhibition of antioxidative enzymes such as GSH, SOD, and GPX. Upstream regulatory mechanisms underlying melatonin-induced antioxidative effects were then examined further. Nrf2 and HO-1 have been identified as the primary antioxidative signaling molecules in endothelial cells. qPCR indicated that ox-LDL treatment significantly decreased Nrf2 and HO-1 transcription (Figures 4(d) and 4(e)), while




FIGURE 4: Melatonin inhibits oxidative stress in ox-LDL-treated endothelial cells. (a–c) ELSIAs were used to measure the activity of antioxidative enzymes such as GSH, GPX, and SOD. (d, e) qPCR was used to analyze Nrf2 and HO-1 transcription in response to ox-LDL treatment with or without melatonin. # $p < 0.05$ vs. the control group, * $p < 0.05$ vs. the ox-LDL group.

melatonin treatment restored Nrf2 and HO-1 levels. Taken together, these results demonstrate that melatonin could reduce oxidative stress in ox-LDL-treated endothelial cells.

3.5. Melatonin Inhibits the JNK/Mff Signaling Pathway in ox-LDL-Treated Endothelial Cells. Finally, we evaluated an upstream signaling pathway that might underlie ox-LDL-induced endothelial dysfunction. Recent studies indicate that the JNK/Mff signaling pathway is associated with inflammation response, cell apoptosis, and oxidative stress in endothelial cells in the context of cardiac ischemia-reperfusion injury. Based on this finding, we examined whether melatonin sustained endothelial function by inhibiting the JNK/Mff signaling pathway. As shown in Figures 5(a)–5(c), western blots demonstrated that ox-LDL activated the JNK pathway as evidenced by increased JNK phosphorylation in endothelial cells. Mff expression was also upregulated in ox-LDL-treated endothelial cells (Figures 5(a)–5(c)). These results indicate that ox-LDL treatment activates the JNK/Mff signaling pathway in endothelial cells. In addition, melatonin inhibited JNK phosphorylation and Mff upregulation in ox-LDL-treated endothelial cells. Immunofluorescence confirmed this finding. As shown in Figures 5(d)–5(f), compared to the control group, ox-LDL increased JNK and Mff immunofluorescence intensity, and melatonin returned both markers to near-normal levels. Overall, these data indicate

that melatonin can inhibit the JNK/Mff signaling pathway in ox-LDL-treated endothelial cells.

4. Discussion

In this study, we found that ox-LDL caused endothelial dysfunction characterized by decreases in cell viability, impaired proliferative capacity, blunted migratory ability, and increases in cell apoptosis rate. Endothelial dysfunction was associated with ER stress, mitochondrial damage, and oxidative stress. At the molecular level, expression of CHOP, PERK, and GRP78 was increased in ox-LDL-treated endothelial cells. Moreover, decreased mitochondrial membrane potential, increased mitochondrial ROS levels, and downregulation of mitochondrial protective factors were observed in ox-LDL-treated endothelial cells. In addition, ox-LDL reduced the activity of antioxidative enzymes and prevented activation of antioxidative signals. Interestingly, melatonin treatment attenuated ox-LDL-induced ER stress, as evidenced by decreased expression of CHOP, PERK, and GRP78. Mitochondrial function and oxidative stress also improved after melatonin administration in ox-LDL-treated endothelial cells. Finally, we found that melatonin protected endothelial cells against ER stress and mitochondrial dysfunction after ox-LDL treatment by inhibiting the JNK/Mff signaling pathway. Taken together, our results demonstrate




FIGURE 5: Melatonin inhibits the JNK/Mff signaling pathway in ox-LDL-treated endothelial cells. (a–c) Proteins were isolated from treated HUVECs and p-JNK and Mff levels were evaluated using western blots. (d, f) Immunofluorescence was used to measure o-JNK and Mff expression in HUVECs treated with melatonin in the presence of ox-LDL. # $p < 0.05$ vs. the control group, * $p < 0.05$ vs. the ox-LDL group.

that ox-LDL promoted endothelial dysfunction by activating ER stress, mitochondrial damage, oxidative stress, and the JNK/Mff signaling pathway. Furthermore, melatonin effectively sustained endothelial cell function by improving ER homeostasis, mitochondrial performance, redox balance, and JNK/Mff axis activity.

ER stress is an adaptive response that affects the quality and quantity of proteins within endothelial cells [57]. When the ER detects the presence of unfolded proteins, CHOP, PERK, and GRP78 expressions increase [58]. Those three proteins then migrate from the ER to the nucleus to interrupt protein transcription more broadly [59]. However, excessive ER stress promotes activation of stress-related proteins such as caspase-12, which is involved in the initiation of cell apoptosis [60]. The relationship between ER stress and endothelial dysfunction has been described in detail in previous studies. For example, ER stress induces interleukin-6 (IL-6) release from endothelial cells, which damages the endothelial barrier [61]. Hypoxia-mediated endothelial cell apoptosis also seems to be associated with ER stress [62]. Additionally,

laminar flow-mediated endothelial protection is associated with inhibition of ER stress through the PI3K/Akt signaling pathway [63]. Our present results further indicate that ER stress contributes to endothelial dysfunction when ox-LDL levels are elevated.

In addition to ER stress, mitochondrial damage or stress also may play a role in endothelial dysfunction. Mitochondria produce ATP to support endothelial cell growth and metabolism [64, 65]. Decreased mitochondrial function has been identified as an early event during endothelial dysfunction [66]. In addition, ATP produced by the mitochondria plays a key regulatory role in endothelia-dependent angiogenesis [67]. In the present study, we found that ox-LDL-induced mitochondrial damage was characterized by mitochondrial membrane potential disruption, mitochondrial ROS overproduction, and downregulation of mitochondrial protective factors. These findings are in accordance with the previous studies [68].

Our data also demonstrate that ER stress and mitochondrial damage could be attenuated by melatonin in endothelial

cells. At the molecular level, the JNK/Mff signaling pathway played a role in melatonin's ability to sustain ER homeostasis and mitochondrial function after ox-LDL treatment. Zhou et al. [27] were the first to report a role for the JNK/Mff signaling pathway in the context of cardiac ischemia-reperfusion injury. In that study, reperfusion injury induced JNK phosphorylation and thus promoted Mff transcription, which was followed by mitochondrial fragmentation, intracellular oxidative stress, and endothelial cell apoptosis [27]. In the present study, we found that the JNK/Mff axis was also activated by ox-LDL and might contribute to ox-LDL-induced endothelial dysfunction. In addition, melatonin treatment inhibited JNK/Mff signaling pathway activity. This finding provides novel insight into the pathological mechanisms underlying ox-LDL-related endothelial dysfunction as well as potential treatments.

In summary, we found that ox-LDL triggered endothelial dysfunction by inducing ER stress, mitochondrial damage, and oxidative stress. Furthermore, melatonin treatment was able to sustain endothelial viability by inhibiting the JNK/Mff signaling pathway and attenuating damage to the ER and mitochondria. Our study thus identified potential targets for clinical treatments that might protect endothelial function.

Data Availability

All data generated or analyzed during this study are included in the published article.

Conflicts of Interest

All authors declare that there are no conflicts of interest associated with this study.

Authors' Contributions

Peng Li and Changlian Xie designed this manuscript and conducted parts of the experiments. Jiankai Zhong and Zhongzhou Guo conducted parts of the experiments and analyzed all the data. Qiuyun Tu, Kai Guo, and Peng Li wrote the manuscript. All the authors approved the submission. Peng Li and Changlian Xie contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation Youth Program, China (Grant No. 81900398), Natural Science Foundation of Guangdong Province, China (Grant No. 2018A030313067), and Medical Scientific Research Foundation of Guangdong Province, China (Grant No. A2020206).

References

- [1] J. Wang, S. Toan, and H. Zhou, "New insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury," *Angiogenesis*, vol. 23, no. 3, pp. 299–314, 2020.
- [2] G. Warpsinski, M. J. Smith, S. Srivastava et al., "Nrf2-regulated redox signaling in brain endothelial cells adapted to physiological oxygen levels: consequences for sulforaphane mediated protection against hypoxia-reoxygenation," *Redox Biology*, vol. 37, article 101708, 2020.
- [3] Y. Zhang, M. Zhang, X. Zhao et al., "NAD administration decreases microvascular damage following cardiac ischemia/reperfusion by restoring autophagic flux," *Basic Research in Cardiology*, vol. 115, no. 5, p. 57, 2020.
- [4] G. Heusch, "Coronary microvascular obstruction: the new frontier in cardioprotection," *Basic Research in Cardiology*, vol. 114, no. 6, p. 45, 2019.
- [5] W. E. Hughes, A. M. Beyer, and D. D. Gutterman, "Vascular autophagy in health and disease," *Basic Research in Cardiology*, vol. 115, no. 4, p. 41, 2020.
- [6] X. Nie, W. Tang, Z. Zhang et al., "Procyanidin B2 mitigates endothelial endoplasmic reticulum stress through a PPAR δ -dependent mechanism," *Redox Biology*, vol. 37, article 101728, 2020.
- [7] H. Zhang, Y. L. Wang, Y. Z. Tan, H. J. Wang, P. Tao, and P. Zhou, "Enhancement of cardiac lymphangiogenesis by transplantation of CD34+VEGFR-3+ endothelial progenitor cells and sustained release of VEGF-C," *Basic Research in Cardiology*, vol. 114, no. 6, p. 43, 2019.
- [8] D. Buglak, E. Kushner, A. Marvin, K. Davis, and V. Bautch, "Excess centrosomes disrupt vascular lumenization and endothelial cell adherens junctions," *Angiogenesis*, vol. 23, no. 4, pp. 567–575, 2020.
- [9] T. Xin, C. Lu, J. Zhang et al., "Oxidized LDL disrupts metabolism and inhibits macrophage survival by activating a miR-9/Drp1/mitochondrial fission signaling pathway," *Oxidative Medicine and Cellular Longevity*, vol. 2020, 16 pages, 2020.
- [10] C. Khatana, N. K. Saini, S. Chakrabarti et al., "Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis," *Oxidative Medicine and Cellular Longevity*, vol. 2020, Article ID 5245308, 14 pages, 2020.
- [11] K. Karolczak and C. Watala, "The mystery behind the pineal gland: melatonin affects the metabolism of cholesterol," *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 4531865, 8 pages, 2019.
- [12] D. Vatner, M. Oydanich, J. Zhang, D. Babici, and S. Vatner, "Secreted frizzled-related protein 2, a novel mechanism to induce myocardial ischemic protection through angiogenesis," *Basic Research in Cardiology*, vol. 115, no. 4, p. 48, 2020.
- [13] S. Yang, M. Wu, X. Li et al., "Role of endoplasmic reticulum stress in atherosclerosis and its potential as a therapeutic target," *Oxidative Medicine and Cellular Longevity*, vol. 2020, 15 pages, 2020.
- [14] K. T. Kubra, M. S. Akhter, M. A. Uddin, and N. Barabutis, "Unfolded protein response in cardiovascular disease," *Cellular Signalling*, vol. 73, article 109699, 2020.
- [15] N. Pastor-Cantizano, D. K. Ko, E. Angelos, Y. Pu, and F. Brandizzi, "Functional diversification of ER stress responses in Arabidopsis," *Trends in Biochemical Sciences*, vol. 45, no. 2, pp. 123–136, 2020.
- [16] H. Zhu, M. Zhao, Y. Chen, and D. Li, "Bcl-2-associated athanogene 5 overexpression attenuates catecholamine-induced vascular endothelial cell apoptosis," *Journal of Cellular Physiology*, vol. 236, no. 2, pp. 946–957, 2021.
- [17] R. Villalobos-Labra, M. Subiabre, F. Toledo, F. Pardo, and L. Sobrevia, "Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabetes," *Molecular Aspects of Medicine*, vol. 66, pp. 49–61, 2019.

- [18] P. Zhu, S. Hu, Q. Jin et al., "Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: a mechanism involving calcium overload/XO/ROS/mPTP pathway," *Redox Biology*, vol. 16, pp. 157–168, 2018.
- [19] H. Zhou, J. Wang, P. Zhu, S. Hu, and J. Ren, "Ripk3 regulates cardiac microvascular reperfusion injury: the role of IP3R-dependent calcium overload, XO-mediated oxidative stress and F-actin/filopodia-based cellular migration," *Cellular Signalling*, vol. 45, pp. 12–22, 2018.
- [20] J. Wang, S. Toan, and H. Zhou, "Mitochondrial quality control in cardiac microvascular ischemia-reperfusion injury: new insights into the mechanisms and therapeutic potentials," *Pharmacological Research*, vol. 156, article 104771, 2020.
- [21] J. Wang and H. Zhou, "Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia-reperfusion injury," *Acta Pharmaceutica Sinica B*, vol. 10, no. 10, pp. 1866–1879, 2020.
- [22] X. Wu, L. Zhang, Y. Miao et al., "Homocysteine causes vascular endothelial dysfunction by disrupting endoplasmic reticulum redox homeostasis," *Redox Biology*, vol. 20, pp. 46–59, 2019.
- [23] H. Zhou, Y. Zhang, S. Hu et al., "Melatonin protects cardiac microvasculature against ischemia/reperfusion injury via suppression of mitochondrial fission-VDAC1-HK2-mPTP-mitophagy axis," *Journal of Pineal Research*, vol. 63, no. 1, article e12413, 2017.
- [24] K. Rao, X. Shen, S. Pardue, and D. Krzywanski, "Nicotinamide nucleotide transhydrogenase (NNT) regulates mitochondrial ROS and endothelial dysfunction in response to angiotensin II," *Redox Biology*, vol. 36, article 101650, 2020.
- [25] M. Winkler, P. Müller, A. M. Sharifi et al., "Functional investigation of the coronary artery disease gene SVEP1," *Basic Research in Cardiology*, vol. 115, no. 6, p. 67, 2020.
- [26] E. Watanabe, T. Wada, A. Okekawa et al., "Stromal cell-derived factor 1 (SDF1) attenuates platelet-derived growth factor-B (PDGF-B)-induced vascular remodeling for adipose tissue expansion in obesity," *Angiogenesis*, vol. 23, no. 4, pp. 667–684, 2020.
- [27] Q. Jin, R. Li, N. Hu et al., "DUSP1 alleviates cardiac ischemia/reperfusion injury by suppressing the Mff-required mitochondrial fission and Bnip3-related mitophagy via the JNK pathways," *Redox Biology*, vol. 14, pp. 576–587, 2018.
- [28] H. Zhou, S. Hu, Q. Jin et al., "Mff-dependent mitochondrial fission contributes to the pathogenesis of cardiac microvasculature ischemia/reperfusion injury via induction of mROS-mediated cardiolipin oxidation and HK2/VDAC1 disassociation-involved mPTP opening," *Journal of the American Heart Association*, vol. 6, no. 3, 2017.
- [29] H. Zhou, J. Wang, P. Zhu et al., "NR4A1 aggravates the cardiac microvascular ischemia reperfusion injury through suppressing FUNDC1-mediated mitophagy and promoting Mff-required mitochondrial fission by CK2 α ," *Basic Research in Cardiology*, vol. 113, no. 4, p. 23, 2018.
- [30] Cochrane Anaesthesia Group, B. K. Madsen, D. Zetner, A. M. Møller, and J. Rosenberg, "Melatonin for preoperative and postoperative anxiety in adults," *Cochrane Database of Systematic Reviews*, vol. 12, article Cd009861, 2020.
- [31] M. Fernández-Ortiz, R. K. A. Sayed, J. Fernández-Martínez et al., "Melatonin/Nrf2/NLRP3 connection in mouse heart mitochondria during aging," *Antioxidants*, vol. 9, no. 12, p. 1187, 2020.
- [32] A. Albazal, A. A. Delshad, and M. Roghani, "Melatonin reverses cognitive deficits in streptozotocin-induced type 1 diabetes in the rat through attenuation of oxidative stress and inflammation," *Journal of Chemical Neuroanatomy*, vol. 112, article 101902, 2021.
- [33] S. W. Wang, H. C. Tai, C. H. Tang et al., "Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression," *Journal of Cellular Physiology*, 2020.
- [34] H. Zhou, D. Li, P. Zhu et al., "Melatonin suppresses platelet activation and function against cardiac ischemia/reperfusion injury via PPAR γ /FUNDC1/mitophagy pathways," *Journal of Pineal Research*, vol. 63, no. 4, 2017.
- [35] H. Zhou, Q. Jin, Y. Li et al., "Melatonin protected cardiac microvascular endothelial cells against oxidative stress injury via suppression of IP3R-[Ca $^{2+}$]_i/VDAC-[Ca $^{2+}$]_m axis by activation of MAPK/ERK signaling pathway," *Cell Stress & Chaperones*, vol. 23, no. 1, pp. 101–113, 2018.
- [36] G. R. Hinrichs, K. Weyer, U. G. Friis et al., "Sodium retention by uPA-plasmin-ENaC in nephrotic syndrome-authors reply," *Acta Physiologica (Oxford, England)*, vol. 228, no. 4, article e13432, 2020.
- [37] H. Zhou, D. Li, P. Zhu et al., "Inhibitory effect of melatonin on necroptosis via repressing the Ripk3-PGAM5-CypD-mPTP pathway attenuates cardiac microvascular ischemia-reperfusion injury," *Journal of Pineal Research*, vol. 65, no. 3, article e12503, 2018.
- [38] S. Liu, J. Chen, J. Shi et al., "M1-like macrophage-derived exosomes suppress angiogenesis and exacerbate cardiac dysfunction in a myocardial infarction microenvironment," *Basic Research in Cardiology*, vol. 115, no. 2, p. 22, 2020.
- [39] V. H. Ko, L. J. Yu, D. T. Dao et al., "Roxadustat (FG-4592) accelerates pulmonary growth, development, and function in a compensatory lung growth model," *Angiogenesis*, vol. 23, no. 4, pp. 637–649, 2020.
- [40] H. Zhou, S. Toan, P. Zhu, J. Wang, J. Ren, and Y. Zhang, "DNA-PKcs promotes cardiac ischemia reperfusion injury through mitigating BI-1-governed mitochondrial homeostasis," *Basic Research in Cardiology*, vol. 115, no. 2, p. 11, 2020.
- [41] J. Wang, P. Zhu, R. Li, J. Ren, and H. Zhou, "Fundc1-dependent mitophagy is obligatory to ischemic preconditioning-conferred renoprotection in ischemic AKI via suppression of Drp1-mediated mitochondrial fission," *Redox Biology*, vol. 30, article 101415, 2020.
- [42] Y. Tan, D. Mui, S. Toan, P. Zhu, R. Li, and H. Zhou, "SERCA overexpression improves mitochondrial quality control and attenuates cardiac microvascular ischemia-reperfusion injury," *Molecular Therapy-Nucleic Acids*, vol. 22, pp. 696–707, 2020.
- [43] S. Gunesch, M. Hoffmann, C. Kiermeier et al., "7-O-Esters of taxifolin with pronounced and overadditive effects in neuroprotection, anti-neuroinflammation, and amelioration of short-term memory impairment in vivo," *Redox Biology*, vol. 29, article 101378, 2020.
- [44] N. Lubos, S. van der Gaag, M. Gerçek, S. Kant, R. E. Leube, and C. A. Krusche, "Inflammation shapes pathogenesis of murine arrhythmogenic cardiomyopathy," *Basic Research in Cardiology*, vol. 115, no. 4, p. 42, 2020.
- [45] E. H. Moon, Y. H. Kim, P. N. Vu et al., "TMEM100 is a key factor for specification of lymphatic endothelial progenitors," *Angiogenesis*, vol. 23, no. 3, pp. 339–355, 2020.

- [46] F. Husain-Syed, M. H. Rosner, and C. Ronco, "Distant organ dysfunction in acute kidney injury," *Acta Physiologica*, vol. 228, article e13357, 2019.
- [47] J. Wang, Z. Chen, Q. Dai et al., "Intravenously delivered mesenchymal stem cells prevent microvascular obstruction formation after myocardial ischemia/reperfusion injury," *Basic Research in Cardiology*, vol. 115, no. 4, p. 40, 2020.
- [48] E. Steffen, W. B. E. Mayer von Wittgenstein, M. Hennig et al., "Murine sca1/flk1-positive cells are not endothelial progenitor cells, but B2 lymphocytes," *Basic Research in Cardiology*, vol. 115, no. 2, p. 18, 2020.
- [49] G. Seano and R. K. Jain, "Vessel co-option in glioblastoma: emerging insights and opportunities," *Angiogenesis*, vol. 23, no. 1, pp. 9–16, 2020.
- [50] H. Zhou, P. Zhu, J. Wang, S. Toan, and J. Ren, "DNA-PKcs promotes alcohol-related liver disease by activating Drp1-related mitochondrial fission and repressing FUNDC1-required mitophagy," *Signal Transduction and Targeted Therapy*, vol. 4, no. 1, p. 56, 2019.
- [51] J. Wang, P. Zhu, S. Toan, R. Li, J. Ren, and H. Zhou, "Pum2-Mff axis fine-tunes mitochondrial quality control in acute ischemic kidney injury," *Cell Biology and Toxicology*, vol. 36, no. 4, pp. 365–378, 2020.
- [52] I. Cuijpers, S. J. Simmonds, M. van Bilsen et al., "Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities," *Basic Res Cardiol*, vol. 115, no. 4, p. 39, 2020.
- [53] Y. Sawashita, N. Hirata, Y. Yoshikawa, H. Terada, Y. Tokinaga, and M. Yamakage, "Remote ischemic preconditioning reduces myocardial ischemia-reperfusion injury through unacylated ghrelin-induced activation of the JAK/STAT pathway," *Basic Research in Cardiology*, vol. 115, no. 4, p. 50, 2020.
- [54] C. Veith, D. Neghabian, H. Luitel et al., "FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction," *Basic Research in Cardiology*, vol. 115, no. 2, p. 17, 2020.
- [55] P. Villacampa, S. E. Liyanage, I. P. Klaska et al., "Stabilization of myeloid-derived HIFs promotes vascular regeneration in retinal ischemia," *Angiogenesis*, vol. 23, no. 2, pp. 83–90, 2020.
- [56] C. Schinner, S. Olivares-Florez, A. Schlipp et al., "The inotropic agent digitoxin strengthens desmosomal adhesion in cardiac myocytes in an ERK1/2-dependent manner," *Basic Research in Cardiology*, vol. 115, no. 4, p. 46, 2020.
- [57] M. Yuan, M. Gong, Z. Zhang et al., "Hyperglycemia induces endoplasmic reticulum stress in atrial cardiomyocytes, and mitofusin-2 downregulation prevents mitochondrial dysfunction and subsequent cell death," *Oxidative Medicine and Cellular Longevity*, vol. 2020, Article ID 6569728, 14 pages, 2020.
- [58] J. Zhang, J. Yang, C. Lin et al., "Endoplasmic reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in pancreatic cancer," *Theranostics*, vol. 10, no. 18, pp. 8400–8414, 2020.
- [59] J. Zhang, R. Saad, E. W. Taylor, and M. P. Rayman, "Selenium and selenoproteins in viral infection with potential relevance to COVID-19," *Redox Biology*, vol. 37, article 101715, 2020.
- [60] Y. Wang, Z. Chen, Y. Li et al., "Low density lipoprotein receptor related protein 6 (LRP6) protects heart against oxidative stress by the crosstalk of HSF1 and GSK3 β ," *Redox Biology*, vol. 37, article 101699, 2020.
- [61] E. Bernhart, N. Kogelnik, J. Prasch et al., "2-Chlorohexadecanoic acid induces ER stress and mitochondrial dysfunction in brain microvascular endothelial cells," *Redox Biology*, vol. 15, pp. 441–451, 2018.
- [62] H. Maekawa and R. Inagi, "Stress signal network between hypoxia and ER stress in chronic kidney disease," *Frontiers in Physiology*, vol. 8, p. 74, 2017.
- [63] S. Kim and C. H. Woo, "Laminar flow inhibits ER stress-induced endothelial apoptosis through PI3K/Akt-dependent signaling pathway," *Molecules and Cells*, vol. 41, no. 11, pp. 964–970, 2018.
- [64] A. Jusic, the EU-CardioRNA COST Action (CA17129), and Y. Devaux, "Mitochondrial noncoding RNA-regulatory network in cardiovascular disease," *Basic Research in Cardiology*, vol. 115, no. 3, pp. 1–17, 2020.
- [65] M. Ding, C. Liu, R. Shi et al., "Mitochondrial fusion promoter restores mitochondrial dynamics balance and ameliorates diabetic cardiomyopathy in an optic atrophy 1-dependent way," *Acta Physiologica (Oxford, England)*, vol. 229, no. 1, article e13428, 2020.
- [66] M. A. Kluge, J. L. Fetterman, and J. A. Vita, "Mitochondria and endothelial function," *Circulation Research*, vol. 112, no. 8, pp. 1171–1188, 2013.
- [67] R. Marcu, Y. Zheng, and B. J. Hawkins, "Mitochondria and angiogenesis," *Advances in Experimental Medicine and Biology*, vol. 982, pp. 371–406, 2017.
- [68] J. D. Marshall, I. Bazan, Y. Zhang, W. H. Fares, and P. J. Lee, "Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both," *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 314, no. 5, pp. L782–L796, 2018.